Cargando…

HOXB3 drives WNT-activation associated progression in castration-resistant prostate cancer

Enabled resistance or innate insensitiveness to antiandrogen are lethal for castration-resistant prostate cancer (CRPC). Unfortunately, there seems to be little can be done to overcome the antiandrogen resistance because of the largely unknown mechanisms. In prospective cohort study, we found that H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Shimiao, Yang, Zhao, Zhang, Zheng, Zhang, Hongli, Li, Songyang, Wu, Tao, Chen, Xuanrong, Guo, Jianing, Wang, Aixiang, Tian, Hao, Yu, Jianpeng, Zhang, Changwen, Su, Lei, Shang, Zhiqun, Quan, Changyi, Niu, Yuanjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042887/ https://www.ncbi.nlm.nih.gov/pubmed/36973255 http://dx.doi.org/10.1038/s41419-023-05742-y

Ejemplares similares

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients
por: Zhang, Zheng, et al.
Publicado: (2018)

YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression
por: Shen, Tianyu, et al.
Publicado: (2020)

CYTOR drives prostate cancer progression via facilitating AR‐V7 generation and its oncogenic signalling
por: Yu, Jianpeng, et al.
Publicado: (2023)

LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex
por: Shang, Zhiqun, et al.
Publicado: (2019)

Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
por: Chen, Xuanrong, et al.
Publicado: (2020)

AB007. Neurotensin derived from cancer stroma contributes to castration resistance via promoting neuroendocrine transdifferentiation
por: Zhu, Shimiao, et al.
Publicado: (2016)

Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3
por: Chen, Xuanrong, et al.
Publicado: (2021)

Increased KIF4A expression is a potential prognostic factor in prostate cancer
por: Gao, Hongwei, et al.
Publicado: (2018)

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022)

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023)

A switch from CD44(+) cell to EMT cell drives the metastasis of prostate cancer
por: Shang, Zhiqun, et al.
Publicado: (2014)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021)

Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival
por: Li, Gang, et al.
Publicado: (2017)

Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer
por: Chen, Xuanrong, et al.
Publicado: (2021)

Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
por: Li, Yang, et al.
Publicado: (2023)

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

Neutrophil–lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis
por: Wang, Zhun, et al.
Publicado: (2018)

Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression
por: Hu, Jieping, et al.
Publicado: (2018)

AB188. Vasohibin-1 and microvessel density predict prognosis in clear cell renal cell carcinoma
por: Tian, Hao, et al.
Publicado: (2016)

AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015)

AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)

Loss of epithelial AR increase castration resistant stem-like prostate cancer cells and promotes cancer metastasis via TGF-β1/EMT pathway
por: Cai, Qiliang, et al.
Publicado: (2020)

Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer
por: Qu, Yanchun, et al.
Publicado: (2016)

YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth
por: Jiang, Ning, et al.
Publicado: (2017)

Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma
por: Gao, Yukui, et al.
Publicado: (2022)

Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies
por: Zhu, Shimiao, et al.
Publicado: (2013)

Development and validation of CT imaging–based preoperative nomogram in the prediction of unfavorable high-grade small renal masses
por: Xie, Hui, et al.
Publicado: (2019)

KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells
por: Shen, Tianyu, et al.
Publicado: (2019)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2021)

Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer
por: Guo, Linpei, et al.
Publicado: (2021)

[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2023)

A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants
por: Jiang, Ning, et al.
Publicado: (2013)

Prostate cancer risk variants of the HOXB genetic locus
por: Dupont, William D., et al.
Publicado: (2021)

YAP is required for prostate development, regeneration, and prostate stem cell function
por: Xie, Hui, et al.
Publicado: (2023)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Correction: A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants
por: Jiang, Ning, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vbgnggtinir1j8h8cu14uamp52